![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Peyrl Andreas
Publisher: Adis International
ISSN: 0312-5963
Source: Clinical Pharmacokinetics, Vol.48, Iss.4, 2009-06, pp. : 265-271
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Brion Annie
Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cytarabine: Blindness following intrathecal administration?: case report
Reactions Weekly, Vol. 1, Iss. 1393, 2012-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cytarabine: Neurological and visual disorders following intrathecal administration: 3 case reports
Reactions Weekly, Vol. 1, Iss. 1228, 2008-01 ,pp. :